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Abstract

Results

Myasthenia Gravis (MG) is an autoimmune disease of the
neuromuscular junction. The purpose of this study was to analyze the
biological pathways and key genetic contributors that lead to MG. In
this study, we performed functional annotation of the significant
variants from the results of an MG Genome-Wide Association (GWAS)
study on a Southeastern European population. Furthermore, the three
approaches used were positional mapping of the SNPs, pathway
analysis, and eQTL mapping. The positional and eQTL mapping were
performed through FUMA. We annotated the SNPs to genes based on
their physical position, and for the eQTL we used data from public
repositories to test whether the expression of the gene is associated
with allelic variation at the SNP. For the pathway analysis we used
MAGMA; first, gene-analysis was performed in order to determine the
p-value per gene based on whether the SNPs included in a gene were
significantly associated with MG. Thirty-five genes were detected by all
three approaches using the early-onset MG cases; all of them are
located in the Major Histocompatibility Complex (MHC) region, which
is reported to be associated with MG in previous studies. Five genes in
the dataset including both early and late onset cases were detected by
all three approaches, one being THEMIS and the other four are located
in the MHC region. Overall, our study supports the results of previous
studies as well as identifying novel risk factors. Further studies into the
functions and mechanisms of these novel genes may allow researchers
to develop therapeutics and treatments which would delay the
progression of the disease or lessen the symptoms.
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Genes Found in All 3 Methods:
N/A
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Genes Found in All 3 Methods: APOM,
ATF6B, ATP6V1G2, BAG6, C2, C6orf48,
CDSN, CFB, CLIC1, CSNK2B, DDR1,
DDX39B, GNL1, GTF2H4, HLA-B, HLADQA1, HLA-DRA, MICA, MICB, MSH5,
NCR3, NOTCH4, PPP1R18, PRRC2A,
PSORS1C1, SFTA2, SLC44A4, STK19,
TCF19, TNXB, TRIM10, TRIM15,
TRIM26, TRIM31, VARS2

Introduction
Myasthenia Gravis (MG) is an autoimmune disease of the
neuromuscular junction. It is a rare disorder which causes muscle
weakness and fatigue, and the typical treatment currently is
anticholinesterase drugs, immunosuppressive drugs or surgery. One of
the characteristics of MG is the early (< 50 years old) vs late (≥ 50 years
old) onset. The onset is found to have been sex-specific, with earlyonset patients usually being females and late-onset patients usually
being males (Gilhus, 2016). The purpose of this study was to analyze
the biological pathways and key genetic contributors that lead to MG.
In this study, we performed functional annotation of the significant
variants from the results of an MG Genome-Wide Association (GWAS)
study on a Southeastern European population. Furthermore, the three
approaches used were positional mapping of the SNPs, pathway
analysis, and eQTL mapping. From all three methods, we were able to
detect five genes that were significantly associated with MG in the
dataset including both early and late onset cases and 35 genes were
detected from the early-onset dataset.
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Genes Found in All 3 Methods:
ATF6B, C2, MSH5, THEMIS, TNXB
Figure 2: Manhattan plots of MAGMA results

Figure 3: Venn Diagrams of overlapping results between
eQTL mapping, positional mapping, and MAGMA methods

Materials
• Summary statistics data from in-house Myasthenia Gravis data set
• 43 MSigDB gene sets related to mechanisms in the development of
MG and autoimmune disorders
• eQTL data from Blood eQTL Browser, BIOS QTL Browser
(information from blood samples), and from GTEx data from samples
of
o EBV-transformed lymphocytes
o whole blood
o skeletal muscle
o tibial nerve
o thyroid
• Chromatin interaction data from neural progenitor cells
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Figure 1: Schematic of Overall Research Approach

In performing this study, we aimed to find significant genes and pathways which are
associated with Myasthenia Gravis. To summarize, our major findings are the 36 genes that
were found in the results of positional mapping, eQTL mapping, and MAGMA from the earlyonset and joint MG dataset; 35 were from the early-onset dataset and one unique gene was
from the joint dataset. Additionally, the BioCarta Complement Pathway was found using
MAGMA gene set-based analysis on the early-onset data. It is likely that these genes and
pathways play some role in the development or progression of Myasthenia Gravis. In the next
steps, we will perform a meta-analysis to determine whether our results overlap with
previous MG studies and, if possible, to detect novel variants. Using these results we can
progress our understanding of the disease. More specifically, further research into the
THEMIS gene may prove useful as it is not located in the MHC region. Additionally, outside
studies into the functions and mechanisms of the genes from our results may allow
researchers to develop therapeutics and treatments which would delay the progression of the
disease or lessen the symptoms.
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